HOME | Alphawatch

top of page

Stock Exchange

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

Jonathan Poyer

8 hours ago2 min read

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

Jonathan Poyer

8 hours ago1 min read

GLP-1s are All the Rage - Let's Dig Into That

GLP-1s are All the Rage - Let's Dig Into That

GLP-1s are All the Rage - Let's Dig Into That

Jonathan Poyer

1 day ago2 min read

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Jonathan Poyer

1 day ago2 min read

When the Shock Absorber Stops Absorbing

When the Shock Absorber Stops Absorbing

When the Shock Absorber Stops Absorbing

Jonathan Poyer

2 days ago4 min read

What are the Medical & Investment Implication of Psychedelics

What are the Medical & Investment Implication of Psychedelics

What are the Medical & Investment Implication of Psychedelics

Jonathan Poyer

2 days ago1 min read

Globus Medical (GMED) Adds AI to Its Surgical Ecosystem

Globus Medical (GMED) Adds AI to Its Surgical Ecosystem

Globus Medical (GMED) Adds AI to Its Surgical Ecosystem

Jonathan Poyer

2 days ago1 min read

Synopsys (SNPS): AI Demand Is Showing Up in the Numbers

Synopsys (SNPS): AI Demand Is Showing Up in the Numbers

Synopsys (SNPS): AI Demand Is Showing Up in the Numbers

Jonathan Poyer

Aug 281 min read

BioMarin (BMRN) Makes a $275 Million Bet on an Oral Treatment for Rare Bone Disease

BioMarin (BMRN) Makes a $275 Million Bet on an Oral Treatment for Rare Bone Disease

BioMarin (BMRN) Makes a $275 Million Bet on an Oral Treatment for Rare Bone Disease

Jonathan Poyer

Aug 281 min read

Gilead (GILD): Don't Let a $(8.45) EPS Number Obscure a +10% Quarter

Gilead (GILD): Don't Let a $(8.45) EPS Number Obscure a +10% Quarter

Gilead (GILD): Don't Let a $(8.45) EPS Number Obscure a +10% Quarter

Jonathan Poyer

Aug 271 min read

Argenx (ARGX) Looks Beyond FcRn with $2.2 Billion Acquisition of Forte Biosciences

Argenx (ARGX) Looks Beyond FcRn with $2.2 Billion Acquisition of Forte Biosciences

Argenx (ARGX) Looks Beyond FcRn with $2.2 Billion Acquisition of Forte Biosciences

Jonathan Poyer

Aug 241 min read

Jazz Pharmaceuticals (JAZZ) Deepens Its Rare Epilepsy Pipeline with Actio Biosciences Acquisition

Jazz Pharmaceuticals (JAZZ) Deepens Its Rare Epilepsy Pipeline with Actio Biosciences Acquisition

Jazz Pharmaceuticals (JAZZ) Deepens Its Rare Epilepsy Pipeline with Actio Biosciences Acquisition

Jonathan Poyer

Aug 241 min read

bottom of page